Development of Drugs for Mitochomdrial Diseases Using Patient's Skin Fibroblasts

Development of Drugs for Mitochomdrial Diseases Using Patient's Skin Fibroblasts - Developing Drgus for Mitochondrial Diseases

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014874

Enrollment

Registered

2014-09-01

Start date

2014-02-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mitochondrial diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients diagnosed with MItochondrial disease

Exclusion criteria

Exclusion criteria: Non patient

Design outcomes

Primary

Measure	Time frame
To isolate and culture Patient's skin fibroblast and examine the protective effect of various newly developped drugs	—

Secondary

Measure	Time frame
Lactic acid and various TCA cycle-related substances accumulate in the blood of patients with mitochondrial disease, and this is also a diagnostic criterion. Therefore, we will measure the blood concentrations of various metabolites from blood and urine samples obtained during the course of treatment of patients, comprehensively analyze the metabolome of intracellular low molecular weight compounds in fibroblasts, and investigate the reactivity of various compounds to stress responses to develop new therapeutic drugs.	—

Measure

Time frame

Lactic acid and various TCA cycle-related substances accumulate in the blood of patients with mitochondrial disease, and this is also a diagnostic criterion. Therefore, we will measure the blood concentrations of various metabolites from blood and urine samples obtained during the course of treatment of patients, comprehensively analyze the metabolome of intracellular low molecular weight compounds in fibroblasts, and investigate the reactivity of various compounds to stress responses to develop new therapeutic drugs.

—

Countries

Japan

Contacts

Public ContactTakaaki ABE

Tohoku University Hospital Division of Clinical Biology and Hormonal Regualtion

takaabe@med.tohoku.ac.jp022-717-7163

Outcome results